Formation Bio

Company · Business

Mentions

Episodes

Claims

Formation Bio, mentioned 8 times across podcast episodes and expert conversations analyzed by Sonic.

What Formation Bio has said

Formation Bio has licensed a fibroblast growth factor 18 (FGF18) drug program from Merck KGA.

bullish·Ben Liu

Formation Bio's initial seed funding was $2.25 million, and its Series A round was $15 million.

neutral·Ben Liu

Formation Bio raised its Series C from investors including Sam Altman and Lockhee, which enabled it to start acquiring drugs directly onto its balance sheet.

bullish·Ben Liu

Formation Bio has licensed a fibroblast growth factor 18 (FGF18) drug program from Merck KGA.

Expert perspectiveBen LiuJul 13

Formation Bio's initial seed funding was $2.25 million, and its Series A round was $15 million.

Expert perspectiveBen LiuJul 13

Formation Bio raised its Series C from investors including Sam Altman and Lockhee, which enabled it to start acquiring drugs directly onto its balance sheet.

Expert perspectiveBen LiuJul 13

Formation Bio partnered with Joe Jiménez, the former CEO of Novartis, to create a fund named Aditum Bio.

Expert perspectiveBen LiuJul 13

Formation Bio was originally named TrialSpark and began as a tech-enabled Contract Research Organization (CRO).

Expert perspectiveBen LiuJul 13

Formation Bio's business model is to acquire already-discovered drugs rather than performing its own discovery.

Expert perspectiveBen LiuJul 13

Formation Bio is structured using a 'hub and spoke' model, which allows it to sell individual drug assets without selling the entire company.

Expert perspectiveBen LiuJul 13

Under the Aditum Bio partnership, Formation Bio received minority equity in each new company formed but did not receive management fees or carry.

Expert perspectiveBen LiuJul 13

Create a free account to see Formation Bio's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail